About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNANCT04168788

Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL

Hepatic veno-occlusive diseases (VOD) during cancer treatment in children are serious toxicities that have occurred with interruptions of chemotherapy and risk of relapse. In addition, these toxicitie...

Lead sponsor: University Hospital, Angers•16 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Denise Jolivot, MD

CONTACT

33-(0)2-41-35-58-08 DeJolivot@chu-angers.fr

Sybille Lazareff, CRA

CONTACT

33-(0)2-41-35-33-42 SyLazareff@chu-angers.fr

Sponsors

Lead Sponsor

University Hospital, Angers

Case-control study, nested in two French multicenter cohorts, on pharmacognenetic, biological and clinical susceptibility factors associated with the occurrence of hepatic veno-occlusive disease during the anticancer treatment for nephroblastoma or acute lymphoblastic leukemia, with centralized genetic analysis. After obtaining consent (patient or parents for minor patients), a blood sample is collected during the routine follow-up consultation and tubes are sent directly to Paris for the pharmacogenetic analysis at the end of the study.

Age

0 - 18 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Children aged \< 18 years old at the time of cancer diagnosis
•Having been treated with a single line of treatment for nephroblastoma or ALL, in France between 2000 and 2018, and who did not receive allogeneic hematopoietic stem cell transplantation
•Weight greater than 5 kg at inclusion
•Informed consent dated and signed by the holder of the parental authority (if minor) or by the patient (if major) to take part in the study
•Affiliated to a Social Security scheme

Exclusion Criteria

•Unavaibility of constitutional DNA
•Person who receive more than one treatment line for nephroblastoma or ALL in childhood or adolescence
•Pregnant, lactating or parturient women
•Person deprived of their liberty by judicial or administrative decision
•Person under psychiatric care under duress
•Person subject to legal protection
•Person unable to express their consent

Related studies

RECRUITINGPhase 1/2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

RECRUITINGPhase 2

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT06390319 · T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, and more

RECRUITINGEARLY Phase 1

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT06735690 · Acute Lymphoblastic Leukemia

Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia

NCT07191119 · Survivor of Childhood Cancer, Insomnia, and more

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

NCT06074666 · Acute Lymphoblastic Leukemia, Pediatric

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 19, 2019Terms

Trial snapshot

StatusUNKNOWN

PhaseNA

Enrollment150

Start dateJan 2020

Last updatedNov 19, 2019

Condition

Hepatic Veno-Occlusive Disease Nephroblastoma Acute Lymphoblastic Leukemia

Locations shown

Univesity Hostipal of Amiens

Amiens

University Hospital of Bordeaux

Bordeaux

University of Brest

Brest

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 19, 2019Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions